Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Camillo Porta
- چاپ و سال / کشور: 2011
Description
Despite being the very first molecular targeted agents registered for the treatment of advanced kidney cancer (in the post-cytokines setting) [1], Sorafenib seemed to lose its momentum as a credible first-line treatment option, when it proved not to be superior to Interferon within a randomized phase II trial [2]. Even though the results of that trial have been highly criticized—mainly due to patient selection bias—these negative results, together with the concomitant availability of other highly active treatments, such as Sunitinib, the combination of Bevacizumab plus Interferon, Temsirolimus (for poor risk patients) and, more recently, also Pazopanib, greatly limited its front-line use almost only to those few patients still treated first-line with cytokines, or to ill-defined, special situations (e.g., elderly patients, patients with cardiovascular co-morbidities, etc.) [3]. As far as second-line, where its use is supported by almost only retrospective, studies [4], the publication of the randomized controlled, phase III trial of Everolimus [5] seemed to have moved Sorafenib back to third, or even subsequent, line.
Oncol Rev DOI 10.1007/s12156-011-0084-1
